Semaglutide vs. Sitagliptin: A Global Head-to-Head for Type 2 Diabetes

Managing Type 2 Diabetes often requires multiple medications to achieve optimal glycaemic control and prevent complications. Metformin is typically the first-line treatment, but many patients need additional therapies. This global clinical trial aimed to compare the efficacy and safety of once-weekly semaglutide against once-daily sitagliptin as an add-on to stable metformin therapy.

The primary objective of this study was to compare the effect of once-weekly Semaglutide versus once-daily Sitagliptin on glycaemic control after 30 weeks of treatment, with safety as a key secondary endpoint. While the provided abstract details the study design and objectives, it does not present specific efficacy or safety data from the trial itself. However, based on the well-established pharmacological profiles and prior research comparing these drug classes, the study was designed to detect significant differences in key metabolic parameters. Previous studies and the known mechanisms of action suggest that Semaglutide (a GLP-1 receptor agonist) would lead to a more substantial reduction in HbA1c (a measure of average blood sugar over 2-3 months), typically in the range of 1.5% to 2.0%, compared to Sitagliptin's (a DPP-4 inhibitor) expected reduction of 0.6% to 0.8%. Furthermore, Semaglutide is known to induce significant weight loss, often around 4 kg to 6 kg over a similar treatment period, whereas Sitagliptin is generally weight-neutral. Regarding safety, while both are generally well-tolerated, Semaglutide is associated with gastrointestinal side effects like nausea and vomiting in a higher percentage of patients (e.g., 20-30% vs. 5-10% for Sitagliptin), which typically diminish over time. The study aimed to confirm that Semaglutide would provide superior glycaemic control and additional benefits like weight reduction compared to Sitagliptin when added to metformin in patients with Type 2 Diabetes.